Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Convallatoxin is a natural cardiac glycoside and small molecule primarily extracted from *Convallaria majalis* (lily of the valley) and *Antiaris toxicaria*. It acts as a potent inhibitor of the Na+/K+-ATPase pump, which leads to an increase in intracellular calcium and a positive inotropic effect on the heart. Historically used in traditional medicine for heart failure and arrhythmias, it is currently utilized primarily as a research tool. Recent studies have explored its potential in oncology (inducing apoptosis and autophagy), inflammatory diseases (colitis), and atherosclerosis (via PPARγ signaling). It is not currently an FDA-approved therapeutic and is not associated with a specific commercial drug development program.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on convallatoxin.